Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3

• Autores: Javier Ampuero, Manuel Romero-Gómez
• Localización: Gastroenterology clinics of North America, ISSN 0889-8553, Vol. 44, Nº. 4, 2015 (Ejemplar dedicado a: Hepatitis C Virus: The Next Epidemic), págs. 845-857
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Hepatitis C virus (HCV) genotypes 2 and 3 have previously been classified as easy-to-treat genotypes, because sustained virologic responses (SVRs) up to 80% have been achieved with 24-week peginterferon and ribavirin. More detailed studies have shown differences between HCV genotypes 2 and 3, indicating that genotype 3 has become the most difficult-to-treat genotype. With new drugs, new challenges are emerging regarding relapse rates, the role of ribavirin, and optimal duration of therapy. Sofosbuvir remains the backbone of genotype 3 therapy, whereas this drug is not an option in patients with creatinine clearance lower than 30 mL/min.